Patent application number | Description | Published |
20080312337 | Anticancer Composition Comprising Obovatol or Obovatal - Disclosed herein is an anticancer composition, comprising obovatol, represented by the following Chemical Formula 1, obovatal, represented by the following Chemical Formula 2, and/or pharmaceutical salts thereof. The composition exhibits the activity of inhibiting the growth of cancer cells and suppressing the expression and activity of matrix metalloproteinases (MMPs), and thus can be useful for the prophylaxis and treatment of cancer as well as for the inhibition of cancer metastasis. | 12-18-2008 |
20090239955 | Novel obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient - Disclosed herein are novel obovatol derivatives represented by Chemical Formula 1, and pharmaceutically acceptable salts thereof. Having the ability to inhibit the growth of cancer cells and induce apoptosis in cancer cells, the derivatives or pharmaceutically acceptable salts thereof are useful in the prevention and treatment of cancer and in the suppression of cancer metastasis. Also, a method for preparing the derivatives, and pharmaceutical compositions comprising the derivatives as active ingredients are disclosed. | 09-24-2009 |
20090263521 | COMPOSITION FOR THE TREATMENT OF CANCERS AND INHIBITION OF METASTASIS CONTAINING EXTRACTS OR FRACTIONS OF THE MAGNOLIA OBOVATA - The present invention relates to a composition containing the extracts of | 10-22-2009 |
20090311354 | COMPOSITION COMPRISING EXTRACTS OR FRACTIONS OF MAGNOLIA OBOVATA THUNB FOR TREATING AND PREVENTING INFLAMMATION DISEASE - The present invention relates to a composition for the prevention and treatment of inflammatory disease containing the extracts of | 12-17-2009 |
20090318376 | High Throughput Screening Method of Binding Inhibitor Between caspase3 and XIAP and Binding Inhibitor Screened Thereby - The present invention relates to a high throughput screening method of a binding inhibitor between caspase3 and xIAP and chromomycin screened using the same, and more specifically, the present invention provides a method for screening anticancer substance, the method comprising the steps of reacting caspase3 or xIAP and candidate inhibitors of the binding between caspase3 and xIAP on a biochip for detecting caspase3:xIAP interaction, and selecting a candidate substance inhibiting the binding of caspase3 to xIAP as an anticancer substance, and an anticancer agent inhibiting caspase3:xIAP binding, which is screened by the above method. According to present invention, it is possible to develop a target-oriented anticancer agent focused on xIAP and caspase3, apoptosis-related proteins and thus it can be applied to tailored medication and combination therapy. Moreover, glycoside antibiotic chromomycin, screened by the present invention has inhibitory activity of the binding between xIAP and caspase3 involved in apoptosis, so that it can be used as a therapeutic agent for myelogenous leukemia and solid tumors. | 12-24-2009 |
20100125103 | COMPOSITION FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME CONTAINING OBOVATOL AND ITS SYNTHESIZED DERIVATIVES - Disclosed is a pharmaceutical composition containing obovatol represented by Formula 1 and its derivatives. The obovatol and its derivatives effectively increase the activity of AMPK (AMP-activated protein kinase) that plays an important role in diabetes and metabolic syndrome, and thus may be variously used in treating diabetes and metabolic syndrome. | 05-20-2010 |
20120130069 | NOVEL INDAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS PROTEIN KINASE INHIBITORS FOR PROLIFERATIVE DISEASES TREATMENT, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT - Disclosed are novel indazole derivatives represented by the following Chemical Formula 1 or pharmaceutically acceptable salts, hydrates or solvates thereof, and pharmaceutical compositions for the prevention or treatment of proliferative diseases, containing the same as an active ingredient. Having potent inhibitory effect against protein kinase, such as b-raf, KDR, Fms, Tie2, SAPK2a and Ret, inducing diseases caused by abnormal cell proliferation, the novel indazole derivatives can be used for the prevention or treatment of diseases caused by abnormal cell proliferation. | 05-24-2012 |
20120184604 | COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES COMPRISING COLFORSIN DAROPATE - The present invention relates to a pharmaceutical composition for the prevention or treatment of bone diseases comprising colforsin daropate, and more particularly, the present invention relates to a pharmaceutical composition for the prevention or treatment of bone diseases such as bone fracture and osteoporosis, which inhibits osteoclast differentiation and bone resorption caused by osteoclasts and promotes osteoblast differentiation and the activity of osteoblasts, and a health functional food composition comprising colforsin daropate. | 07-19-2012 |
20130245068 | COMPOSITION COMPRISING BENPROPERINE DERIVATIVES AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING ANGIOGENESIS-RELATED DISEASES - The present invention relates to a novel pharmaceutical composition of benproperine derivatives for preventing and treating angiogenesis-related diseases. The benproperine derivatives and pharmaceutically acceptable salts thereof according to the present invention inhibit cancer cell migration and the angiogenesis of vascular endothelial cells, and therefore can be effectively used not only as an anticancer agent, but also as an agent for preventing and treating diseases caused by abnormal angiogenesis, such as diabetic retinopathy and corneal transplant rejection. | 09-19-2013 |